GenSight Biologics Confirms 2nd Successful GMP Batch of LUMEVOQ® and Eligibility to Draw Down Bridge Financing 2nd Tranche of €4 million

GenSight Biologics Reports Cash Position as of September 30, 2023, and Provides Business Update

GenSight Biologics Reports Interim Financial Results for the First Half of 2023

GenSight Biologics obtains funding of €10 million from Sofinnova Partners, Invus and UPMC Enterprises

GenSight Biologics Provides Financial and Operational Update

Annual General Meeting on June 21, 2023

GenSight Biologics Withdraws its EMA Application for LUMEVOQ®

GenSight Biologics to Host a Webcast on April 5, 2023, to Provide an Update on LUMEVOQ® Manufacturing Following Investigations Findings

GenSight Biologics Reports Full Year 2022 Consolidated Financial Results

GenSight Biologics Provides Update on LUMEVOQ® Manufacturing and Commercialization Timelines